AIHealthcare

Deep Genomics is a privately held AI-first biotechnology and TechBio company developing genetic medicines through artificial intelligence, genomics, RNA biology, and laboratory workflows. Its platform—described on the company’s website as a Biological Foundation Model (BioFM) Platform and previously as the AI Workbench—combines AI model development, biological datasets, screening technologies, automation, and lab-in-the-loop validation to identify disease mechanisms, therapeutic targets, and RNA-based drug candidates. The company’s stated market position is as an integrated AI-driven drug-discovery and genetic-medicine developer focused particularly on RNA therapeutics and genetically defined diseases, rather than as a general-purpose healthcare software provider. Deep Genomics has offices in Toronto and Cambridge, Massachusetts, and remains private. Its latest publicly disclosed major financing is a $180 million Series C announced in July 2021; third-party databases report total funding in the approximate $227 million–$241 million range, so the exact cumulative total is not consistently reported.